Artificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial [0.03%]
乳腺癌局部区域治疗支持共同决策的AI云平台：嵌入CINDERELLA临床试验的多维度评估实施方案
Ludovica Borsoi,Elisabetta Listorti,Oriana Ciani;CINDERELLA Consortium
Ludovica Borsoi
Background: Shared decision-making (SDM) plays a crucial role in breast cancer care by empowering patients and reducing decision regret. Patient decision aids (PtDAs) are valuable tools for facilitating SDM, now available...
Healthcare Resource Utilization and Associated Costs During the First 5 Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland [0.03%]
芬兰多发性骨髓瘤患者诊断后的前五年和生命末期的卫生资源利用及相关的费用：一项全国队列研究
Mikko Kosunen,Jarno Ruotsalainen,Alvar Kallio et al.
Mikko Kosunen et al.
Background: The burden associated with the treatment of patients with multiple myeloma (MM) is expected to increase due to the aging population. Thus, policymakers and clinicians need a holistic view of the healthcare res...
Clinicians' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment [0.03%]
基于临床管理考量下的神经节苷脂受体调节剂用于多发性硬化治疗的优劣选择：一种实验方法
Alexander Keenan,Chiara Whichello,Hoa H Le et al.
Alexander Keenan et al.
Background: Four sphingosine-1-phosphate receptor (S1PR) modulators are currently available in the USA for treating relapsing forms of multiple sclerosis (MS). These S1PR modulators have similar efficacy. Clinicians may t...
Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK [0.03%]
英国慢性口服皮质类固醇使用者的不良事件建模
Danny Gibson,Neil Branscombe,Neil Martin et al.
Danny Gibson et al.
Background: Oral corticosteroids (OCS) are effective anti-inflammatory agents used across a range of conditions. However, substantial evidence associates their use with increased risks for adverse events (AEs), causing hi...
The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System [0.03%]
RefluxStop治疗难治性胃食管反流病对意大利医疗卫生系统的经济影响
Sam Harper,Muralikrishnan Kartha,Stuart Mealing et al.
Sam Harper et al.
Introduction: Gastroesophageal reflux disease (GERD) is a common ailment associated with troublesome symptoms. The standard of care in Italy involves initial treatment with proton pump inhibitor (PPI)-based medical manage...
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain [0.03%]
西班牙BRCA1/2突变高危HER2阴性早期乳腺癌患者使用奥拉帕利辅助治疗的成本效益分析
Sergio Cedillo,Almudena González-Domínguez,Yoana Ivanova-Markova et al.
Sergio Cedillo et al.
Objective: Here we estimate the cost-effectiveness of olaparib in the Spanish National Health Service (SNHS) as adjuvant treatment of early germline mutations in the BRCA1/2 genes (gBRCAm) HER2-negative (HER2neg) breast c...
Otavio Clark,Tulio Sarmento,Anthony Eccleston et al.
Otavio Clark et al.
Introduction: Incidence and mortality for bladder cancer has changed very little over the past 20 years. Approximately 40% of patients with high-risk nonmuscle invasive bladder cancer eventually recur/progress. It is impo...
A Systematic Review of the Impact of Spinal Cord Injury on Costs and Health-Related Quality of Life [0.03%]
系统性回顾：脊髓损伤对费用和健康相关生活质量的影响
Modou Diop,David Epstein
Modou Diop
Objective: To systematically review the health-related quality of life (HRQoL) burden and costs of spinal cord injury (SCI) on health services, patients and wider society. ...
Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico [0.03%]
墨西哥四期非小细胞肺癌疾病负担的估计分析
Denisse Añorve Bailon,Javier Picó-Guzmán,Sergio Cifuentes et al.
Denisse Añorve Bailon et al.
Introduction: Lung cancer continues to be the leading cause of death among cancer patients worldwide. This study aimed to estimate the clinical, economic, and social burdens of stage IV non-small cell lung cancer (NSCLC) ...
Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers' Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses [0.03%]
2018至2022年加拿大非肿瘤药物卫生技术评估报告：对生产商提交资料的方法学批评以及生产商和加拿大药品与医疗器械机构（CADTH）分析结果的对比
Fatemeh Mirzayeh Fashami,Jean-Eric Tarride,Behnam Sadeghirad et al.
Fatemeh Mirzayeh Fashami et al.
Introduction: Identifying key differences between manufacturers' submitted analysis and economic reanalysis by the Canadian Agency for Drugs and Technologies in Health (CADTH) is an important step toward understanding rei...